Actively Recruiting
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Led by Grit Biotechnology · Updated on 2026-04-15
83
Participants Needed
24
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
CONDITIONS
Official Title
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand study requirements and provide written informed consent
- Female aged 18 to 70 years at consent
- Confirmed diagnosis of unresectable recurrent or metastatic cervical carcinoma
- Received at least one prior systemic therapy
- ECOG performance status of 0 or 1
- Expected survival time of at least 12 weeks
- Adequate normal organ and marrow function
- Documented disease progression since last treatment before tumor resection
- Measurable disease by RECIST 1.1 criteria besides resected lesion
You will not qualify if you...
- Uncontrollable tumor-related pain or unstable pain management
- Psychiatric disorders or substance abuse
- Pregnant, breastfeeding, or planning pregnancy within 1 year after cell infusion
- Participation in other clinical trials within 4 weeks prior to screening or planning concurrent trial participation
- Any other condition making participation unsuitable as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
The Fifth Medical Center of the General Hospital of the People's Liberation Army of China
Beijing, Beijing Municipality, China, 222002
Actively Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
3
Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital
Shenzhen, Guangdong, China, 518172
Actively Recruiting
4
Guangxi Medical University Affiliated Cancer Hospital
Guilin, Guangxi, China, 530021
Actively Recruiting
5
Harbin Medical University Affiliated Cancer Hospital
Ha’erbin, Heilongjjiang, China, 150081
Actively Recruiting
6
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China, 450052
Actively Recruiting
7
Henan Cancer Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
8
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
9
Xiangya Second Hospital of Central South University
Changsha, Hunan, China, 410012
Actively Recruiting
10
Southeast University Affiliated Zhongda Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
11
Jiangxi Maternal and Child Health Hospital
Nanchang, Jiangxi, China, 330006
Actively Recruiting
12
Affiliated Zhongshan Hospital Dalian University
Dalian, Liaoning, China, 116001
Actively Recruiting
13
Dalian Medical University First Affiliated Hospital
Dalian, Liaoning, China, 116001
Actively Recruiting
14
Shandong First Medical University Affiliated Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
15
Jining First People's Hospital
Jining, Shandong, China, 272002
Actively Recruiting
16
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
17
Fudan University Affiliated Obstetrics and Gynecology Hospital
Shanghai, Shanghai Municipality, China, 214432
Actively Recruiting
18
Shanxi Cancer Hospital
Taiyuan, Shanxi, China, 030013
Actively Recruiting
19
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China, 710061
Actively Recruiting
20
Sichuan University West China Second Hospital
Chengdu, Sichuan, China, 610044
Actively Recruiting
21
Yibin Second People's Hospital
Yibin, Sichuan, China, 644002
Actively Recruiting
22
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China, 300181
Actively Recruiting
23
Yun Cancer Hospital
Kunming, Yunnan, China, 650118
Actively Recruiting
24
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310005
Actively Recruiting
Research Team
X
XiaoHua Wu, PHD
CONTACT
J
Jing Wang, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here